GlaxoSmithKline, Novartis, Roche, and Eli Lilly have joined forces to invest venture capital into Aileron Therapeutics, a biotech company based in Cambridge, MA that is using novel chemical structures to make a new class of medicines. GSK, Novartis, Roche and Lilly are all investing in a $40 million fundraising by the company. Aileron’s synthetically locked (or “stapled”) peptides, in theory, will be able to target biochemical pathways involved in cell function and disease that co...